{
  "ticker": "JNJ",
  "target_date": "2025-10-07",
  "actual_date": "2025-10-07",
  "collected_at": "2025-12-08T12:22:23.948734",
  "price": {
    "open": 182.61,
    "high": 188.04,
    "low": 181.79,
    "close": 187.69825744628906,
    "volume": 8776800,
    "change_1d_pct": 0.39,
    "change_7d_pct": 5.11,
    "change_30d_pct": 6.65
  },
  "technicals": {
    "rsi_14": 75.6,
    "sma_20": 179.04,
    "sma_50": 175.27,
    "macd": 3.473,
    "macd_signal": 2.5,
    "macd_histogram": 0.972,
    "bb_upper": 189.08,
    "bb_lower": 168.99,
    "price_vs_sma20_pct": 4.84,
    "price_vs_sma50_pct": 7.09,
    "volume_ratio": 0.99
  },
  "fundamentals": {
    "market_cap": 487858176000,
    "pe_ratio": 19.545368,
    "forward_pe": 19.10283,
    "price_to_book": 6.1459317,
    "price_to_sales": 5.294232,
    "profit_margin": 27.26,
    "operating_margin": 30.2,
    "roe": 33.62,
    "roa": 8.26,
    "revenue_growth": 6.8,
    "earnings_growth": 91.0,
    "debt_to_equity": 57.766,
    "current_ratio": 1.074,
    "quick_ratio": 0.711,
    "dividend_yield": 258.0,
    "fifty_two_week_high": 207.81,
    "fifty_two_week_low": 140.68,
    "fifty_day_avg": 193.4922,
    "two_hundred_day_avg": 170.2741,
    "analyst_target": 203.41833,
    "analyst_recommendation": "buy",
    "num_analysts": 24,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -2.56,
    "pct_from_52w_low": 43.94
  },
  "macro": {
    "spy": {
      "price": 669.12,
      "change_1d_pct": -0.37,
      "change_7d_pct": 0.82
    },
    "vix": {
      "level": 17.24,
      "signal": "NORMAL"
    },
    "treasury_10y": {
      "yield_pct": 4.13
    },
    "dollar_index": {
      "level": 98.58
    },
    "gold": {
      "price": 3976.6
    },
    "regime": "BULL_NORMAL"
  },
  "news": [
    {
      "headline": "LA County Jury Hits Johnson & Johnson with Nearly $1 Billion Verdict",
      "source": "Yahoo",
      "datetime": 1759868340,
      "summary": "LOS ANGELES, October 07, 2025--A Los Angeles County jury has returned damages totaling $966 million, including $950 million in punitive damages, to the family of Mae Moore, who died of mesothelioma in 2021 after using Johnson & Johnson\u2019s iconic baby powder.",
      "url": "https://finnhub.io/api/news?id=6d058011145c64d9770d7ee05319977ee22d9a72c03b9e1cf46ff9f7de7d6c1c"
    },
    {
      "headline": "Sector Update: Health Care Stocks Edge Down Late Afternoon",
      "source": "Yahoo",
      "datetime": 1759866669,
      "summary": "Health care stocks edged lower late Tuesday afternoon, with the NYSE Health Care Index and the Healt",
      "url": "https://finnhub.io/api/news?id=e56d8938bc9062ca5aefbd8d375463e339a0f05b9b58c10f8b0d7c1580487c67"
    },
    {
      "headline": "The Zacks Analyst Blog Highlights Microsoft, Amazon.com, Johnson & Johnson and Willis Lease Finance",
      "source": "Yahoo",
      "datetime": 1759844040,
      "summary": "Zacks Analyst Blog highlights Microsoft, Amazon, Johnson & Johnson, and Willis Lease Finance as analysts weigh AI growth, pharma resilience, and niche leasing strength.",
      "url": "https://finnhub.io/api/news?id=8bf34fd1d27c7df8b7a0f36e777600f3a5900514a1baed879b85d5d8292bedb3"
    },
    {
      "headline": "Prudential Financial (PRU): Assessing Valuation as Fundamental Challenges Draw Renewed Investor Scrutiny",
      "source": "Yahoo",
      "datetime": 1759842923,
      "summary": "Prudential Financial (PRU) has landed in the spotlight as investors take a closer look at its fundamentals. This follows news of shrinking net premiums, tepid book value growth, and a rising debt-to-equity ratio. See our latest analysis for Prudential Financial. Amid Prudential Financial\u2019s ongoing b",
      "url": "https://finnhub.io/api/news?id=6b2147e6656b06e206e9fbaf9413bd1d9fe5cc2487491c9a18785a9f94428003"
    },
    {
      "headline": "TREMFYA\u00ae (guselkumab) is first and only IL-23 inhibitor to demonstrate sustained clinical and endoscopic outcomes with a fully subcutaneous regimen through 48 weeks in ulcerative colitis",
      "source": "Yahoo",
      "datetime": 1759838700,
      "summary": "Johnson & Johnson (NYSE: JNJ) today announced new 48-week data from the Phase 3 ASTRO study evaluating TREMFYA\u00ae (guselkumab) subcutaneous (SC) induction and maintenance therapy in adults with moderately to severely active ulcerative colitis (UC). These data show clinically meaningful rates of clinic",
      "url": "https://finnhub.io/api/news?id=d55f5c0dce3d962221b8f469a395beb0ba2909ca6e46b49a6b2d938931ce6c73"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2025-09-11",
      "description": "xslF345X05/wk-form4_1757627547.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000196/xslF345X05/wk-form4_1757627547.xml"
    },
    {
      "form": "4",
      "date": "2025-09-11",
      "description": "xslF345X05/wk-form4_1757627315.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000194/xslF345X05/wk-form4_1757627315.xml"
    },
    {
      "form": "4",
      "date": "2025-09-11",
      "description": "xslF345X05/wk-form4_1757627206.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000192/xslF345X05/wk-form4_1757627206.xml"
    },
    {
      "form": "8-K",
      "date": "2025-09-09",
      "description": "jnj-20250908.htm",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000190/jnj-20250908.htm"
    },
    {
      "form": "4",
      "date": "2025-09-05",
      "description": "xslF345X05/wk-form4_1757109644.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000186/xslF345X05/wk-form4_1757109644.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}